Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Researchers identify new way to prevent chemotherapy resistance in lung and breast cancers

Researchers identify new way to prevent chemotherapy resistance in lung and breast cancers

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Study highlights racial/ethnic disparities in genomic sequencing

Study highlights racial/ethnic disparities in genomic sequencing

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Patients with EGFR-mutated lung cancer benefit more from afatinib as first-line treatment

Post-progression afatinib exposure boosts NSCLC outcomes

Post-progression afatinib exposure boosts NSCLC outcomes

Lancet study compares prices of new cancer drugs in high-income countries

Lancet study compares prices of new cancer drugs in high-income countries

Findings suggest  link between cancer drug resistance and reactive oxygen species found in mitochondria

Findings suggest link between cancer drug resistance and reactive oxygen species found in mitochondria

AstraZeneca presents lung cancer research data at WCLC 2015

AstraZeneca presents lung cancer research data at WCLC 2015

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Researchers identify promising combination strategy for treating glioblastomas

Researchers identify promising combination strategy for treating glioblastomas

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib